{"type":"trials","record":{"id":86134,"source_id":"isrctn","external_id":"ISRCTN16300009","title":"Description of the quality of life of patients with neovascular age-related macular degeneration initiating or switching to faricimab in the real-world setting","brief_summary":"The primary objective of this study is as follows: To evaluate the Health Related Quality of Life of patients suffering from nAMD, initiating or switching to faricimab, after 12-months of faricimab treatment in the real-world setting The secondary objectives of this study are as follows: 1. To describe patient and disease characteristics 2. To assess the disease burden 3. To evaluate the effectiveness of faricimab on visual acuity 4. To evaluate the effectiveness of faricimab on anatomical outcome measurements using optical coherence tomography 5. To describe faricimab treatment patterns 6. To describe the economic impact of the treatment for patients and informal caregivers The safety objective for this study is as follows: To evaluate the ocular and non-ocular safety of faricimab in nAMD in real conditions of use The exploratory objectives are as follows: 1. To search for predictive factors associated with an improvement in HRQoL or disease burden 2. Identify subgroups of patients with similar trends in HRQoL or disease burden, using clustering methods","overall_status":"Not Yet Recruiting","phases":["Not Applicable"],"study_type":"Observational","sponsor":"Roche (France)","enrollment":0,"countries":["France"],"start_date":"2026-10-15","completion_date":"2030-04-15","last_update_date":"2026-09-04","source_url":"https://www.isrctn.com/ISRCTN16300009","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:21.717702+00:00","last_seen_at":"2026-09-26T12:27:04.896+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN16300009; retrieved 2026-09-26","interventions":["Faricimab","Biological/Vaccine"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":[],"design_description":"Observational","source_has_results":false},"controlled_terms":["Patient suffering from neovascular age-related macular degeneration.","The FARILIFE study is a French, national, multicenter, prospective, primary data collection, non-interventional study o…","Faricimab","Biological/Vaccine"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-26T12:27:05.193853+00:00","duplicate_cluster_key":"id:isrctn16300009","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-10-15 to 2030-04-15","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-26T12:27:04.897Z","intervention":["Faricimab","Biological/Vaccine"],"participants":0,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":[],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86134","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}